AU2006319716B2 - Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation - Google Patents

Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation Download PDF

Info

Publication number
AU2006319716B2
AU2006319716B2 AU2006319716A AU2006319716A AU2006319716B2 AU 2006319716 B2 AU2006319716 B2 AU 2006319716B2 AU 2006319716 A AU2006319716 A AU 2006319716A AU 2006319716 A AU2006319716 A AU 2006319716A AU 2006319716 B2 AU2006319716 B2 AU 2006319716B2
Authority
AU
Australia
Prior art keywords
group
carbon atoms
compound
formula
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006319716A
Other languages
English (en)
Other versions
AU2006319716A1 (en
Inventor
Stephane Branchaud
Guy Milot
Brent Richard Stranix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taimed Biologics Inc
Original Assignee
Taimed Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taimed Biologics Inc filed Critical Taimed Biologics Inc
Publication of AU2006319716A1 publication Critical patent/AU2006319716A1/en
Application granted granted Critical
Publication of AU2006319716B2 publication Critical patent/AU2006319716B2/en
Assigned to TAIMED BIOLOGICS, INC. reassignment TAIMED BIOLOGICS, INC. Request for Assignment Assignors: AMBRILIA BIOPHARMA INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2006319716A 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation Ceased AU2006319716B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74064205P 2005-11-30 2005-11-30
US60/740,642 2005-11-30
PCT/CA2006/001963 WO2007062526A1 (en) 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation

Publications (2)

Publication Number Publication Date
AU2006319716A1 AU2006319716A1 (en) 2007-06-07
AU2006319716B2 true AU2006319716B2 (en) 2012-02-02

Family

ID=38091843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006319716A Ceased AU2006319716B2 (en) 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation

Country Status (8)

Country Link
US (2) US8227450B2 (https=)
EP (1) EP1971615B1 (https=)
JP (1) JP2009517412A (https=)
CN (1) CN101405293B (https=)
AU (1) AU2006319716B2 (https=)
CA (1) CA2632095A1 (https=)
ES (1) ES2452718T3 (https=)
WO (1) WO2007062526A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2452718T3 (es) * 2005-11-30 2014-04-02 Taimed Biologics, Inc. Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
WO2008023273A2 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
CA2664118A1 (en) * 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Protease inhibitors
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
EP2435037B1 (en) 2009-05-27 2014-11-12 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6704058B2 (ja) * 2016-05-31 2020-06-03 タイメド・バイオロジクス・インコーポレイテッドＴａｉＭｅｄ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． プロテアーゼ阻害剤の長時間作用性医薬組成物
US10369129B2 (en) 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025592A1 (en) * 2004-08-02 2006-02-02 Stranix Brent R Lysine based compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013861A (en) * 1985-02-28 1991-05-07 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
CZ61893A3 (en) 1990-10-11 1994-01-19 Boehringer Ingelheim Kg Cyclopeptides, process of their preparation and their use as medicaments
US5614522A (en) * 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
RU2146668C1 (ru) * 1992-08-25 2000-03-20 Джи Ди Сирл энд Компани Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидное соединение, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз
DE69311810T2 (de) * 1992-08-25 1997-11-27 Monsanto Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
US6022994A (en) * 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JPH06321950A (ja) 1993-05-14 1994-11-22 Takeda Chem Ind Ltd 水溶性ランカシジン誘導体
AU6548294A (en) 1993-08-31 1995-03-22 Stanley Kugell Telephone billing method
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2210889C (en) * 1995-01-20 2007-08-28 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5985870A (en) * 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0882022A1 (en) 1996-01-26 1998-12-09 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5859061A (en) 1997-01-17 1999-01-12 Pharmacia & Upjohn Company Bis-sulfonamides hydroxamic acids as MMP inhibitors
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EA200000702A1 (ru) * 1997-12-24 2000-12-25 Вертекс Фармасьютикалз Инкорпорейтед Пролекарства ингибиторов аспартилпротеаз
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
JP4814427B2 (ja) 1999-02-12 2011-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼのインヒビター
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
AU778825B2 (en) * 1999-06-16 2004-12-23 Temple University - Of The Commonwealth System Of Higher Education (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors
US6506786B2 (en) * 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
EP1480941B1 (en) 2002-03-04 2011-01-26 Ambrilia Biopharma Inc. Urea derivatives as hiv aspartyl protease inhibitors
CA2374362C (en) * 2002-03-04 2008-01-22 Brent Richard Stranix Urea derivatives as hiv aspartyl protease inhibitors
WO2004054586A1 (en) 2002-12-16 2004-07-01 Boehringer Ingelheim International Gmbh Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US6632816B1 (en) 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
BRPI0418306B8 (pt) 2004-01-08 2021-05-25 Medivir Ab composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n’-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1
ES2319996T3 (es) 2004-08-02 2009-05-18 Ambrilia Biopharma Inc. Compuestos basados en lisina.
WO2006114001A1 (en) 2005-04-27 2006-11-02 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
ES2452718T3 (es) 2005-11-30 2014-04-02 Taimed Biologics, Inc. Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
WO2008023273A2 (en) 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
CA2664118A1 (en) * 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025592A1 (en) * 2004-08-02 2006-02-02 Stranix Brent R Lysine based compounds

Also Published As

Publication number Publication date
EP1971615A1 (en) 2008-09-24
CN101405293B (zh) 2013-03-13
EP1971615A4 (en) 2011-06-22
CN101405293A (zh) 2009-04-08
WO2007062526A8 (en) 2007-08-30
EP1971615B1 (en) 2014-01-01
ES2452718T3 (es) 2014-04-02
HK1124861A1 (en) 2009-07-24
WO2007062526A1 (en) 2007-06-07
US8580995B2 (en) 2013-11-12
CA2632095A1 (en) 2007-06-07
JP2009517412A (ja) 2009-04-30
AU2006319716A1 (en) 2007-06-07
US20100130765A1 (en) 2010-05-27
US20090253926A1 (en) 2009-10-08
US8227450B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
US8580995B2 (en) Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
US8008297B2 (en) Lysine based compounds
US20120053139A1 (en) Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
AU2009230800A1 (en) Lysine based compounds
CA2657316A1 (en) Method for improving pharmacokinetics
HK1124861B (en) Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation
RU2379312C2 (ru) Соединения на основе лизина, фармацевтическая композиция, содержащая эти соединения, применение указанных соединений для лечения или профилактики вич инфекции
ZA200607352B (en) Lysine based compounds
HK1105406B (en) Lysine based compounds
NZ552853A (en) Lysine based compounds
CN102093411A (zh) 基于赖氨酸的化合物
KR20070057815A (ko) 리신계 화합물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAIMED BIOLOGICS, INC.

Free format text: FORMER OWNER WAS: AMBRILIA BIOPHARMA INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired